Nexplanon Duration of Effectiveness
Nexplanon is now FDA-approved and effective for up to 5 years of contraceptive protection 1.
Current FDA Approval
The etonogestrel implant (Nexplanon) received extended FDA approval in 2024 for 5 years of use, expanding from the previous 3-year approval 1. This represents a significant change in the labeled duration based on robust clinical trial data.
Evidence Supporting 5-Year Efficacy
FDA Label Data
The most recent FDA drug label clearly states that Nexplanon is indicated for prevention of pregnancy for up to 5 years 1. Clinical trial data supporting this extension showed:
- Zero pregnancies occurred in years 4 and 5 among 399 women studied 1
- Pearl Index of 0.0 (95% CI: 0.00-0.69) pregnancies per 100 woman-years during years 4-5 1
- Mean etonogestrel serum concentrations remained at 123 pg/mL at year 4 and 111 pg/mL at year 5—well above ovulation suppression thresholds 1
Supporting Research Evidence
Multiple high-quality studies corroborate the 5-year effectiveness:
- A large multicenter randomized trial with 390 women using the ENG implant for extended duration found 100% efficacy through 5 years with no pregnancies 2
- A prospective cohort study of 291 implant users documented zero pregnancies during years 4 and 5 of use, with serum etonogestrel levels remaining above the 90 pg/mL ovulation threshold across all BMI categories 3
Clinical Implications
The implant must be removed by the end of the fifth year and may be replaced with a new implant at the time of removal if continued contraception is desired 1. This extended duration:
- Reduces the frequency of replacement procedures
- Improves cost-effectiveness
- Decreases patient inconvenience and procedural risks
- Maintains the same excellent safety profile (failure rate <1%) 4
Important Caveats
Drug Interactions
While the implant is effective for 5 years in most women, efficacy may be reduced in women taking certain antiretroviral medications, particularly efavirenz-containing regimens 5. Case reports document contraceptive failures in women on efavirenz, though the exact risk remains incompletely quantified. Consider additional or alternative contraception in these patients.
Recent Pregnancy Reports
Despite FDA approval and strong trial data, two case reports from 2026 documented pregnancies occurring in year 4 of use (at 3 years 1 month and 3 years 5 months post-insertion), including one ectopic pregnancy 6. This suggests that while rare, failures can occur during extended use, and further surveillance for risk factors is warranted.
Body Weight Considerations
Women with BMI ≥30 kg/m² have relatively lower etonogestrel serum concentrations (ratio 0.76-0.88 compared to BMI <30), though substantial overlap exists between groups and no pregnancies occurred in obese women during the 5-year trial 1. The implant remains highly effective across all weight categories studied.